Introduction
============

Phosphaturic mesenchymal tumor (PMT) is a polymorphous group of extremely rare mesenchymal tumors that often result in hypophosphatemic osteomalacia/rickets, caused by the overproduction of the phosphaturic hormone fibroblast growth factor 23 (FGF23) ([@b1-ol-0-0-7945]--[@b7-ol-0-0-7945]). PMTs occur more frequently in middle-aged adults, although the age of the patients can range from 3 to 73 years, and are originated predominantly from soft tissue or bone involving a single site ([@b8-ol-0-0-7945],[@b9-ol-0-0-7945]). The vast majority of PMTs are benign, small, subcutaneous and undetectable on physical examination ([@b10-ol-0-0-7945]--[@b12-ol-0-0-7945]). The female to male ratio in patients with PMT is 1:1.2. The most common subtype of PMT is the mixed connective tissue, which accounts for \>70% of cases ([@b13-ol-0-0-7945]).

Historically, it has been documented that many kinds of mesenchymal neoplasms have been classically associated with tumor-induced osteomalacia (TIO) ([@b14-ol-0-0-7945],[@b15-ol-0-0-7945]). TIO, also known as oncogenic osteomalacia, is a rare paraneoplastic syndrome in which vitamin D-resistant osteomalacia occurs due to the presence of a tumor ([@b16-ol-0-0-7945]). Therefore, in addition to distinguishing the four different histological subtypes of PMTs previously described ([@b17-ol-0-0-7945]), it is more important to discriminate this neoplasm from other vascular tumors preoperatively. Furthermore, these tumors frequently occur in variable odd locations making discovery very difficult. As a consequence, these tumors remain a largely misdiagnosed, ignored or unknown entity by most radiologists and clinicians.

Owing to the rarity of PMT, our knowledge of imaging features of this entity has come mostly from the context of case reports or very small case series in the endocrinology, osteology, nuclear medicine, and pathology literature. There have been \>300 cases of PMTs described in the literature so far ([@b16-ol-0-0-7945]). While many of these studies have focused on the pathologic characterization and whole-body imaging modalities of choice in the investigation of PMTs, to the best of our knowledge, there have been no prior reports on the computed tomography (CT) and magnetic resonance imaging (MRI) features of PMTs in the radiology literature. Based on clinical and laboratory examination, musculoskeletal radiologists can originally make the diagnosis of PMTs given the typical CT and MRI findings, but unfortunately the diagnosis has appeared to be often delayed in the radiology community.

To overcome this diagnostic problem, the current study discusses three cases of PMT-MCT in the soft tissue using routine MRI examination. All three patients presented with nonspecific clinical presentation, including diffuse pain, myalgia, muscle spasms, muscle weakness and fatigue. In the current case report, the CT and MRI findings of the three patient cases, for diagnosing the soft-tissue tumor, are described. Furthermore, a comprehensive review of the clinicopathological features of PMTs that have been previously reported in the medical literature is discussed.

Case report
===========

### Case 1

A 59-year-old male presented with a five-year history of fatigue and generalized muscle pain ([Table I](#tI-ol-0-0-7945){ref-type="table"}). He was admitted to the First Affiliated Hospital of Fujian Medical University (Fuzhou, China) in August 2016. The long-term muscle pain became increasingly worse with temporary relief from physiotherapy and analgesics. Routine blood test was performed at the time of admission with the results of hypophosphatemia, normal calcium and parathyroid hormone (PTH) levels ([Table II](#tII-ol-0-0-7945){ref-type="table"}). Slightly elevated cystatin-C and an elevation of alkaline phosphatase (ALP) were noted ([Table II](#tII-ol-0-0-7945){ref-type="table"}). The preoperative bone metabolism markers were presented in [Table III](#tIII-ol-0-0-7945){ref-type="table"}. A clinical diagnosis of hypophosphatemic osteomalacia of unknown etiology was considered and treatment with oral phosphorus and high-dose vitamin D was initiated. A whole-body Tc bone scintigraphy scan was performed as a first step and no lesions were identified. Additional whole-body ^18^F-fludeoxyglucose (FDG) positron emission tomography (PET)/CT scan was ordered to detect the causative tumor. A promising focus of intense FDG uptake was detected in the right ankle ([Fig. 1](#f1-ol-0-0-7945){ref-type="fig"}). The CT scan revealed a small round homogeneous soft-tissue mass, which was located between the distal end of the tibia and fibula and thought to be a PMT ([Fig. 2](#f2-ol-0-0-7945){ref-type="fig"}). Subsequent MRI revealed a small subcutaneous tumor (1.2×1.1×0.9 cm), which appeared isointense to the muscles on T1-weighted imaging, slightly hyperintense on T2-weighted imaging, markedly hyperintense on short tau inversion recovery (STIR) coronal imaging ([Fig. 3](#f3-ol-0-0-7945){ref-type="fig"}), and displayed homogeneous enhancement on postcontrast T1-weighted fat-suppression imaging ([Fig. 4](#f4-ol-0-0-7945){ref-type="fig"}). The tumor was radically resected and diagnosed as PMT-MCT pathologically ([Fig. 5](#f5-ol-0-0-7945){ref-type="fig"}; [Table IV](#tIV-ol-0-0-7945){ref-type="table"}). [Table V](#tV-ol-0-0-7945){ref-type="table"} lists the levels of postoperative bone mentalism markers and ALP at 8 months following surgery. Muscle pain was relieved quickly after the operation, and serum phosphorus levels gradually recovered to normal.

### Case 2

A 52-year-old female presented with left posterior chest pain for the duration of ten years. She was admitted to the First Affiliated Hospital of Fujian Medical University (Fuzhou, China) in July 2008. Further physical examination revealed a large left chest wall tumor involving the 9--11th ribs. The serum bone metabolism markers were presented in [Table III](#tIII-ol-0-0-7945){ref-type="table"}. A whole-body Tc bone scintigraphy scan was used to identify a potential tumor of osteomalacia. An area of abnormal absence of uptake in the 10th rib and slight increased uptake in the 9th and 11th rib were observed. The patient was subsequently referred for plain CT and contrast-enhanced MRI scans for evaluation. The axial CT of the chest revealed a large poorly circumscribed mass (14×9×8 cm). The lesion appeared heterogeneously hypointense on T1WI, hyperintense on fat-saturated T2WI containing prominent vascular flow voids, and marked heterogeneous enhancement on fat-saturated T1-weighted sequences ([Fig. 6](#f6-ol-0-0-7945){ref-type="fig"}). Surgical resection of the lesion was conducted, and the pathologic findings confirmed a PMT-MCT with no evidence of malignancy ([Fig. 7](#f7-ol-0-0-7945){ref-type="fig"}; [Table IV](#tIV-ol-0-0-7945){ref-type="table"}). [Table V](#tV-ol-0-0-7945){ref-type="table"} lists the levels of postoperative bone mentalism markers and ALP at 8 months following surgery. The patient recovered well during the postoperative period, and the chest pain diminished over time. Furthermore, preoperative serum phosphate levels were marked low at 0.38 mmol/l (normal range, 0.81--1.55 mmol/l) and the levels normalized to 1.1 mmol/l at 2 months after the surgery ([Table II](#tII-ol-0-0-7945){ref-type="table"}).

### Case 3

A 59-year-old female presented with left chest muscle spasms with pain which worsened progressively for the duration of one year. She was admitted to the First Affiliated Hospital of Fujian Medical University (Fuzhou, China) in April 2016. On admission, no significant abnormality was observed on physical examination. No muscle atrophy was found initially. Laboratory data disclosed hypophosphatemia with a serum phosphorus level of 0.68 mmol/l (normal range, 0.81--1.55 mmol/l), with normal serum PTH and calcium levels ([Table II](#tII-ol-0-0-7945){ref-type="table"}). Urinary excretion of phosphorus over 24 h increased to 8.91 mmol/l (normal range, 0.96--1.62 mmol/l).

Radiographs of her bones revealed diffused demineralization and DEXA bone densitometry scan revealed marked decrease of bone density in both lumbar spine (0.751 g/cm2; T-score, −3.6) and left femoral neck (0.439 g/cm^2^; T-score, −4.5). A whole-body Tc bone scintigraphy scan was performed and it demonstrated a focal area of increased uptake in the 10th rib. The patient began taking phosphorus and high-dose vitamin D orally. One month later, her condition did not improve considerably. Extensive radiology evaluation including CT and MR scan was performed. Axial CT scan revealed a small soft-tissue mass (1.5×1.5×0.5 cm) in the lower posterior chest wall. The neoplasm appeared homogeneously isointense on T1WI, hyperintense on fat-saturated T2WI ([Fig. 8](#f8-ol-0-0-7945){ref-type="fig"}), and marked homogeneous enhancement on fat-saturated T1-weighted sequences. Subsequent surgical resection was conducted, and the neoplasm was removed and the surgical specimen was pathologically diagnosed to be a PMT-MCT ([Fig. 9](#f9-ol-0-0-7945){ref-type="fig"}; [Table IV](#tIV-ol-0-0-7945){ref-type="table"}). Four days after the operation serum phosphorus levels normalized to 0.82 mmol/l, and one month after the operation muscle pain was completely relieved. [Table V](#tV-ol-0-0-7945){ref-type="table"} lists the levels of postoperative ALP at 8 months after surgery.

Discussion
==========

### Clinicopathological features and tumor detection

The clinical symptoms of PMTs are nonspecific and typically include, but not limited to, diffused pain, muscle weakness, pathologic bone fracture, motor weakness, skeletal deformities, height loss and generalized debilitated state secondary to osteomalacia ([@b18-ol-0-0-7945]--[@b24-ol-0-0-7945]). In addition, patients often present with a firm, slow-growing, unpalatable soft-tissue mass when the tumors arise within the extremities ([@b25-ol-0-0-7945]--[@b27-ol-0-0-7945]). Approximately 53% of reported cases occur in the bone, \~45% in soft tissue, and \~2% in the skin ([@b28-ol-0-0-7945]--[@b32-ol-0-0-7945]). The typical biochemical parameters are hypophosphatemia resulting from renal phosphate wasting, an inappropriately low serum 1,25-dihydroxyvitamin D~3~, normal 25-hydroxyvitamin D~3~, normal or slightly low serum calcium and elevated ALP levels ([@b8-ol-0-0-7945],[@b25-ol-0-0-7945],[@b33-ol-0-0-7945]--[@b35-ol-0-0-7945]). The clinical and biochemical characteristics of the patients presented in the current report were similar to those observed in previously published literature, in which the tumor was situated elsewhere in the body. In case 1, a slightly elevated serum Cystatin-C was also observed, associated with renal tubule damage.

Pathologically, four morphologic patterns of PMTs have been described and widely accepted: primitive-appearing mixed connective tissue, osteoblastoma-like, nonossifying fibroma-like, and ossifying fibroma-like ([@b10-ol-0-0-7945],[@b11-ol-0-0-7945],[@b17-ol-0-0-7945],[@b36-ol-0-0-7945],[@b37-ol-0-0-7945]). It is now believed that the latter three variants may reflect different bone-specific reaction patterns considered within the spectrum of PMT-MCTs ([@b38-ol-0-0-7945]--[@b40-ol-0-0-7945]). The classic microscopic characterization of a PMT-MCT is that of a variably prominent vascular proliferation of plump oval, spindled to stellate cells with generally low nuclear grade, and very low or usually absent mitotic activity. The spindled cells are typically embedded distinctively within a 'grungy', calcified, myxoid to chondromyxoid matrix and often include other findings, including osteoclast-like giant cells, mature fat cells, chondroid or osteoid-like matrix, poorly developed cartilage or bone, areas of hemorrhage and microcysts. Histopathology analysis reveals that pancytokeratin, desmin, S-100 and CD34 are not expressed in the tumor cells ([@b13-ol-0-0-7945],[@b27-ol-0-0-7945],[@b31-ol-0-0-7945],[@b41-ol-0-0-7945],[@b42-ol-0-0-7945]), similar to what was observed in the present cases.

In order to identify the causative tumor of TIO, multiple noninvasive imaging techniques, such as ultrasonography, whole body CT and MRI, ^18^F-FDG PET/CT, ^201^Tl scintigraphy, ^99m^Tc-MIBI SPECT, ^99m^Tc bone scintigraphy, ^111^In-pentetreotide or octreotide scintigraphy, ^99m^Tc-HYNIC-TOC scan, and ^68^Ga-DOTATATE PET/CT have been pursued ([@b23-ol-0-0-7945],[@b43-ol-0-0-7945]--[@b54-ol-0-0-7945]). Recently, ^68^Ga-DOTANOC is firstly deemed as a sufficiently sensitive and specific in detecting an occult tumor ([@b43-ol-0-0-7945],[@b46-ol-0-0-7945]). In China, however, since somatostatin-based functional scans are not approved, ^18^F-FDG PET/CT and ^99m^Tc bone scintigraphy are usually used when diagnosing mesenchymal tumors ([@b55-ol-0-0-7945]).

### CT and MR features and differential diagnosis

The majority of the published literature on imaging studies of PMTs is focused on the choice of optical imaging modality in localizing the tumor, not on the imaging features of PMTs. On CT scans, the tumor exhibits a round/oval, well-bordered, isodense/hypodense soft tissue mass and displays a uniform enhancement when the tumor is small ([@b45-ol-0-0-7945],[@b56-ol-0-0-7945]), similar to what was observed in the present cases. The typical MR appearances of PMT-MCT are isointense relative to the muscles on T1-weighted imaging and markedly hyperintense on T2-weighted imaging, with markedly homogenous enhancement on post contrast T1-weighted fat-suppression imaging. However, the variable tumor sizes result in different MRI imaging features. PMT-MCT with small tumor size displays homogenous signal intensity on both T2WI and T1WI and uniform enhancement on post-contrast T1WI. In contrast, a large tumor displays heterogeneous signal intensity on T2WI and T1WI and heterogeneous enhancement on post-contrast T1WI. The areas of heterogeneous low signals are consistent with vascular flow voids within large tumors.

Case 2 had a large chest mass and the tumor displayed an oval, poorly-bordered, isodense mass on CT scan, heterogeneously decreased signal intensity on T1WI, increased signal intensity on T2WI containing multiple abnormal tortuous vascular flow voids with a vivid enhancement, validated by pathology that the tumor contained prominently vascular components with abundant giant cells. The lesions were clearly depicted as high signal intensity on both STIR and diffusion weighted imaging (DWI), however, the findings were considered nonspecific. Since DWI may have resulted from T2 shine-through effect and has poor spatial resolution, high solution STIR sequence should be the optimal sequence in localizing the tumor ([@b8-ol-0-0-7945],[@b57-ol-0-0-7945]--[@b59-ol-0-0-7945]).

In the present cases, the neoplasms occurred in soft tissue and followed a benign clinical course. The differential possibilities for PMT-MCTs include any soft tissue mass, such as neurofibroma, hemangioendothelioma, fibroma, neurofibrosarcoma, hemangioma, leiomyoma, giant cell tumor, giant cell reparative granuloma, tenosynovitis, ganglion cyst, histiocytoma, desmoid tumor and neuroma. On the basis of histologic and pathologic findings, radiological features and the characteristic clinical signs, the neoplasms were concluded to be PMT-MCTs, which show similar morphology to those soft-tissue tumors previously reported.

To the best of our knowledge, this is the first report of radiological and histological description of a large PMT-MCT (Case 2), which arises from chest wall and causes oncogenic osteomalacia. Thus, it appears to be essential that this entity should be considered among the chest wall tumors.

### Treatment and prognosis

The PMT-MCT frequently has an infiltrating growth pattern, as reported in the present cases, and this may explain the high rates of local recurrence ([@b44-ol-0-0-7945],[@b60-ol-0-0-7945]--[@b64-ol-0-0-7945]). Early, complete surgical resection remains the definitive treatment of PMT-MCTs. It has been previously reported that \~90% of patients with PMT-MCTs are cured by excision ([@b20-ol-0-0-7945],[@b34-ol-0-0-7945],[@b65-ol-0-0-7945]--[@b67-ol-0-0-7945]). All three of the current patients were treated with surgery, which led to the normalization of serum phosphate levels and resolution of symptoms. A key point of surgery is the total removal of the tumor. Wide negative margins are essential for preventing local recurrence of PMT-MCTs, even though bone resection may be required. In addition, intralesional treatment is insufficient to control the tumors occurring in bone and radical resection should be planned. However, local recurrence and metastasis after surgical resection have been described. Although malignant transformation of PMT-MCTs is extremely rare ([@b12-ol-0-0-7945]), the patient experienced multiple recurrence and developed histologic features that were highly suggestive of high-grade status, hypercellularity, and increased mitotic activity transformation of primary benign tumors.

Medical therapy with phosphorus and calcitriol is often given after incomplete resection of the tumor, resulting in anatomic restrictions or medical comorbidities. Although somatostatin receptors have been identified on PMT-MCTs, octreotide therapy, which was based on decreasing FGF23 secretion, has not been effective. Periodic measurement of serum phosphate and FGF23 levels has been advocated as a means to detect recurrences ([@b3-ol-0-0-7945],[@b60-ol-0-0-7945],[@b68-ol-0-0-7945]).

The prognosis for most patients with PMT-MCTs is good; however, a delay in the diagnosis and surgical treatment can increase the overall mortality rates associated with this tumor ([@b69-ol-0-0-7945],[@b70-ol-0-0-7945]).

In conclusion, the present report suggested that once patients have been diagnosed with oncogenic osteomalacia, a whole-body screening scan, such as ^68^Ga-DOTANOC or ^18^F-FDG PET/CT, should be performed to search for the underlying causative tumor, especially when this occurs in an odd location. After identifying the tumor with functional imaging, anatomic imaging analysis, such as CT or MRI, should be used to investigate the radiological features of the tumor and define the exact location.
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![Axial ^18^F-FDG PET/CT scan reveals a small subcutaneous focus of intense FDG uptake (red arrow) in the right ankle. FDG, fludeoxyglucose; PET/CT, positron emission tomography/computed tomography.](ol-15-04-4970-g00){#f1-ol-0-0-7945}

![Computed tomography scan reveals a small round homogeneous isodense soft-tissue mass (1.2×1.1×0.9 cm; red arrow) located between the distal end of the tibia and fibula.](ol-15-04-4970-g01){#f2-ol-0-0-7945}

![A phosphaturic mesenchymal tumor-mixed connective tissue with small tumor size appears markedly uniform hyperintense on short tau inversion recovery coronal imaging.](ol-15-04-4970-g02){#f3-ol-0-0-7945}

![A phosphaturic mesenchymal tumor-mixed connective tissue displays homogeneous vivid enhancement on postcontrast T1-weighted fat-suppression imaging.](ol-15-04-4970-g03){#f4-ol-0-0-7945}

![Histological examination of the phosphaturic mesenchymal tumor-mixed connective tissue in Case 1 exhibits swirling bundles of spindle cells with moderate atypia, greater mitotic activity, scattered multinucleated giant cells, and focal matrix production. A representative image is shown from hematoxylin & eosin staining at ×10 original magnification.](ol-15-04-4970-g04){#f5-ol-0-0-7945}

![A phosphaturic mesenchymal tumor-mixed connective tissue with large tumor size (14×9×8 cm) displays markedly heterogeneous enhancement on fat-saturated T1-weighted sequence containing prominent vascular component.](ol-15-04-4970-g05){#f6-ol-0-0-7945}

![Histological examination of the phosphaturic mesenchymal tumor-mixed connective tissue in Case 2 exhibits bland spindle cells, prominent vascularity, and focal matrix production with stellate cells. A representative image is shown from hematoxylin & eosin staining at ×10 original magnification.](ol-15-04-4970-g06){#f7-ol-0-0-7945}

![A phosphaturic mesenchymal tumor-mixed connective tissue with small tumor size (1.5×1.5×0.5 cm) located in the tenth intercostal space appears uniform hyperintense on fat-saturated T2-weighted imaging.](ol-15-04-4970-g07){#f8-ol-0-0-7945}

![Histological examination of the phosphaturic mesenchymal tumor-mixed connective tissue in Case 3 reveals similar characteristics to Case 2, with bland spindle cells, prominent vessels, and a focal matrix production. A representative image is shown from hematoxylin & eosin staining at ×10 original magnification.](ol-15-04-4970-g08){#f9-ol-0-0-7945}

###### 

Patient demographics and phosphaturic mesenchymal tumor diagnostic characteristics.

  Patient   Age at time of diagnosis (years)   Sex      Tumor location (soft tissue)   Size (cm)      Presenting symptom                           Time to diagnosis (years)   Pathologic fracture
  --------- ---------------------------------- -------- ------------------------------ -------------- -------------------------------------------- --------------------------- ---------------------
  Case 1    59                                 Male     Right ankle joint              1.2×1.1×0.9    Fatigue, generalized muscle pain             5                           No
  Case 2    52                                 Female   Left posterior chest           14.0×9.0×8.0   Left posterior chest pain                    10                          No
  Case 3    59                                 Female   Left posterior chest           1.5×1.5×0.5    Left chest noticed muscle spasms with pain   1                           No

###### 

Preoperative laboratory values.

  Patient        Serum phosphate (mmol/l)   Calcium (mmol/l)   PTH (pmol/l)   CRP (mg/l)   ALP (U/l)   ESR (mm/h)   Cystatin-C (mg/l)   GFR (ml/min)   Urine Bence-Jones protein   Treatment   Postoperative serum phosphate (mmol/l)
  -------------- -------------------------- ------------------ -------------- ------------ ----------- ------------ ------------------- -------------- --------------------------- ----------- ----------------------------------------
  Case 1         0.46                       2.20               4.36           1.87         294         17           1.12                125.96         Negative                    Surgery     1.28
  Case 2         0.38                       2.31               5.32           2.65         334         3            0.56                175.70         Negative                    Surgery     1.1
  Case 3         0.52                       2.17               5.83           3.41         282         22           n/a                 81.42          Negative                    Surgery     0.82
  Normal range   0.81--1.55                 2.03--2.54         1.6--6.9       0--8         45--125     0--15        0.40--1.10          \>80                                                   0.81--1.55

PTH, Parathyroid Hormone; CRP, C-reactive protein; ALP, alkaline phosphatase; ESR, erythrocyte sedimentation rate; GFR, glomerular filtration rate; n/a, not available.

###### 

Preoperative bone mentalism markers.

  Patient        Total 25-hydroxy vitamin D (ng/ml)                                                                Osteocalcin (ng/ml)   Beta-CrossLaps (ng/ml)   TPINP (ng/ml)
  -------------- ------------------------------------------------------------------------------------------------- --------------------- ------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------
  Case 1         35.09                                                                                             33.09                 0.95                     103.60
  Case 2         5.6                                                                                               19.77                 0.599                    39.61
  Normal range   20--70 (\<5 marked decrease; 5--10 modest decrease; 10--20 slight decrease; \>200 intoxication)   14--46                0--0.704                 16.89--65.491 (pre-menopause, 5.13--58.59; post-menopause with HRT treatment, 14.28--58.92; post-menopause without HRT treatment, 20.25--76.31)

TPINP, total procollagen type 1 N-terminal propeptide; HRT, hormone replacement therapy.

###### 

Pathological features and imaging modalities.

                     Immunohistochemical findings                                                
  -------- --------- ------------------------------ ---- ---- ---- ---- --- ---- --- ------- --- ---------------------------------
  Case 1   PMT-MCT   \+                             \+   \+   \+   −    −   −    −   \+ 5%   −   Tc bone scintigraphy+PET/CT+MRI
  Case 2   PMT-MCT                                  \+   \+   \+   −    −        −   \+ 5%   −   Tc bone scintigraphy+CT+MRI
  Case 3   PMT-MCT   \+                             \+   \+   \+   \+   −   \+         2%        Tc bone scintigraphy+CT+MRI

PMT-MCT, phosphaturic mesenchymal tumors-mixed connective tissue; SMA, smooth muscle actin; CK, cytokeratin; P63, tumor protein 63; EMA, epithelial membrane antigen; PET/CT, positron emission tomography/computed tomography; MRI, magnetic resonance imaging.

###### 

Postoperative (8 months) bone mentalism marker and ALP levels.

  Patient        Total 25-hydroxy vitamin D (ng/ml)                                                                Osteocalcin (ng/ml)   beta-CrossLaps (ng/ml)   TPINP (ng/ml)                                                                                                                                     ALP (U/l)
  -------------- ------------------------------------------------------------------------------------------------- --------------------- ------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  Case 1         28.27                                                                                             35.12                 0.65                     38.27                                                                                                                                             199
  Case 2         9.25                                                                                              17.54                 0.43                     39.61                                                                                                                                             223
  Case 3         −                                                                                                 −                     −                        −                                                                                                                                                 207
  Normal range   20--70 (\<5 marked decrease; 5--10 modest decrease; 10--20 slight decrease; \>200 intoxication)   14--46                0--0.70                  16.89--65.491 (pre-menopause, 5.13--58.59; post-menopause with HRT treatment, 14.28--58.92; post-menopause without HRT treatment, 20.25--76.31)   45--125

ALP, alkaline phosphatase; TPINP, total procollagen type 1 N-terminal propeptide; HRT, hormone replacement therapy.
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